Multiple Flavonoid-binding Sites Within Multidrug Resistance Protein MRP1

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2003 Nov 18

PMID 14618263

Citations 9

Authors

D Trompier

H Baubichon-Cortay

X-B Chang

M Maitrejean

D Barron

J R Riordon

A di Pietro

Affiliations

Soon will be listed here.

Abstract

Recombinant nucleotide-binding domains (NBDs) from human multidrug resistance protein MRP1 were overexpressed in bacteria and purified to measure their direct interaction with high-affinity flavonoids, and to evaluate a potential correlation with inhibition of MRP1-mediated transport activity and reversion of cellular multidrug resistance. Among different classes of flavonoids, dehydrosilybin exhibited the highest affinity for both NBDs, the binding to N-terminal NBD1 being prevented by ATP. Dehydrosilybin increased vanadate-induced 8-N3-[alpha-32P]ADP trapping, indicating stimulation of ATPase activity. In contrast, dehydrosilybin strongly inhibited leukotriene C4 (LTC4) transport by membrane vesicles from MRP1-transfected cells, independently of reduced glutathione, and chemosensitized cell growth to vincristine. Hydrophobic C-isoprenylation of dehydrosilybin increased the binding affinity for NBD1, but outsite the ATP site, lowered the increase in vanadate-induced 8-N3-[alpha-32P]ADP trapping, weakened inhibition of LTC4 transport which became glutathione dependent, and induced some cross-resistance. The overall results indicate multiple binding sites for dehydrosilybin and its derivatives, on both cytosolic and transmembrane domains of MRP1.

Citing Articles

Structural basis for the modulation of MRP2 activity by phosphorylation and drugs.

Mazza T, Roumeliotis T, Garitta E, Drew D, Rashid S, Indiveri C Nat Commun. 2024; 15(1):1983.

PMID: 38438394 PMC: 10912322. DOI: 10.1038/s41467-024-46392-8.

Molecular Pathways Involved in the Anti-Cancer Activity of Flavonols: A Focus on Myricetin and Kaempferol.

Felice M, Maugeri A, De Sarro G, Navarra M, Barreca D Int J Mol Sci. 2022; 23(8).

PMID: 35457229 PMC: 9026553. DOI: 10.3390/ijms23084411.

A simple gene set-based method accurately predicts the synergy of drug pairs.

Hsu Y, Chiu Y, Chen Y, Hsiao T, Chuang E BMC Syst Biol. 2016; 10 Suppl 3:66.

PMID: 27585722 PMC: 5009556. DOI: 10.1186/s12918-016-0310-3.

Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer.

Rungsardthong K, Mares-Samano S, Penny J Bioinformation. 2012; 8(19):907-11.

PMID: 23144549 PMC: 3488831. DOI: 10.6026/97320630008907.

Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

Wink M, Ashour M, El-Readi M Front Microbiol. 2012; 3:130.

PMID: 22536197 PMC: 3332394. DOI: 10.3389/fmicb.2012.00130.

References

Wattigney W, Mensah G, Croft J . Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol. 2002; 155(9):819-26. DOI: 10.1093/aje/155.9.819. View

Fuster V, Ryden L, Asinger R, Cannom D, Crijns H, Frye R . ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice.... Eur Heart J. 2001; 22(20):1852-923. DOI: 10.1053/euhj.2001.2983. View

Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger F . Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation. 2004; 111(2):127-35. DOI: 10.1161/01.CIR.0000151289.73085.36. View

Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D . Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation. 2008; 117(6):732-42. DOI: 10.1161/CIRCULATIONAHA.107.730101. View

Goette A, Breithardt G, Fetsch T, Hanrath P, Klein H, Lehmacher W . Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design. Clin Drug Investig. 2007; 27(10):697-705. DOI: 10.2165/00044011-200727100-00005. View

Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W . Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J. 2005; 150(5):899. DOI: 10.1016/j.ahj.2005.07.020. View

McNamara R, Brass L, Drozda Jr J, Go A, Halperin J, Kerr C . ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.... J Am Coll Cardiol. 2004; 44(2):475-95. DOI: 10.1016/j.jacc.2004.06.041. View

El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U . Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation. 2006; 114(7):670-80. DOI: 10.1161/CIRCULATIONAHA.106.636845. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology.... Eur Heart J. 2006; 27(16):1979-2030. DOI: 10.1093/eurheartj/ehl176. View

10.

Cappato R, Calkins H, Chen S, Davies W, Iesaka Y, Kalman J . Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005; 111(9):1100-5. DOI: 10.1161/01.CIR.0000157153.30978.67. View

11.

Fetsch T, Bauer P, Engberding R, Koch H, Lukl J, Meinertz T . Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004; 25(16):1385-94. DOI: 10.1016/j.ehj.2004.04.015. View

12.

Nieuwlaat R, Capucci A, Camm A, Bertil Olsson S, Andresen D, Davies D . Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26(22):2422-34. DOI: 10.1093/eurheartj/ehi505. View

13.

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener H . Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007; 9(11):1006-23. DOI: 10.1093/europace/eum191. View

14.

Kirchhof P, Eckardt L, Franz M, Monnig G, Loh P, Wedekind H . Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol. 2003; 14(10):1027-33. DOI: 10.1046/j.1540-8167.2003.03165.x. View

15.

Wang T, Massaro J, Levy D, Vasan R, Wolf P, DAgostino R . A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290(8):1049-56. DOI: 10.1001/jama.290.8.1049. View

16.

Wolf P, Abbott R, Kannel W . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-8. DOI: 10.1161/01.str.22.8.983. View

17.

Chen S, Hsieh M, Tai C, Tsai C, Prakash V, Yu W . Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation. 1999; 100(18):1879-86. DOI: 10.1161/01.cir.100.18.1879. View

18.

Bertaglia E, Zoppo F, Tondo C, Colella A, Mantovan R, Senatore G . Early complications of pulmonary vein catheter ablation for atrial fibrillation: a multicenter prospective registry on procedural safety. Heart Rhythm. 2007; 4(10):1265-71. DOI: 10.1016/j.hrthm.2007.06.016. View

19.

Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T . The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005; 112(24):3697-706. DOI: 10.1161/CIRCULATIONAHA.105.575332. View

20.

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener H . Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007; 28(22):2803-17. DOI: 10.1093/eurheartj/ehm358. View